Flamel Technologies SA (FLML) Soars: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:39AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 7% on the day.
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:54AM CDT
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 14, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Flamel Technologies Has Returned 16.3% Since SmarTrend Recommendation (FLML)
Comtex SmarTrend(R) - Thu Apr 10, 9:23AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on March 18th, 2014 at $12.42. In approximately 3 weeks, Flamel Technologies has returned 16.26% as of today's recent price of $14.44.
Flamel Technologies (FLML) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:51AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 10% on the day.
/CORRECTION - Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate
Marketwire - Mon Apr 07, 8:16AM CDT
In news release "Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate" issued earlier today by Flamel Technologies (NASDAQ: FLML), we are advised by the company that the first paragraph has changed. Complete corrected text follows.
Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate
Marketwire - Mon Apr 07, 6:31AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that its First-in-Man (FIM) clinical study in healthy volunteers using its proprietary Micropump(R) technology applied to sodium oxybate has identified formulations that demonstrate the potential to eliminate the second nighttime dose for patients suffering from narcolepsy achieved the objective of one single dose before bedtime for patients suffering from narcolepsy, eliminating the need for a second dose. The current dosing regimen for the standard of care, Xyrem(R) (sodium oxybate), in the United States is two equal, divided doses: the first dose at bedtime and the second dose 2.5 to 4 hours later. The elimination of the second dose for narcolepsy patients would not only provide more convenience, but may improve the benefit sodium oxybate provides as there will be no disruption to nighttime sleep. The potential for additional benefits, including improved safety, will be studied.
Flamel Technologies posts lesser adjusted net loss of USD0.1m for Q4 2013
M2 - Wed Mar 26, 7:52AM CDT
Drug delivery company Flamel Technologies (NASDAQ:FLML) stated on Tuesday its adjusted net loss of USD0.1m for the fourth quarter 2013.
Flamel Technologies Announces Fourth Quarter and Full Year 2013 Results
Marketwire - Tue Mar 25, 6:31AM CDT
Flamel Technologies (NASDAQ: FLML) today announced its financial results for the fourth quarter and full year 2013. Highlights from the quarter include:
Flamel (FLML) Catches Eye: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:25AM CDT
Flamel Technologies was a big mover last session, with shares rising nearly 11% on the day.
Can Flamel Technologies (FLML) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:59AM CDT
Can Flamel Technologies (FLML) Continue to Rise?
Flamel Technologies (FLML) Hits $10 a Share: Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:50AM CDT
Flamel Technologies just hit a fresh high moving above the psychologically-important $10 per share level,but we have seen pretty negative consensus estimate trend as of late
Flamel Technologies to Report Fourth Quarter and Fiscal Year 2013 Results and Conference Call
Marketwire - Mon Mar 17, 3:05PM CDT
Flamel Technologies (NASDAQ: FLML) expects to release financial results for the fourth quarter and fiscal year 2013 on Tuesday, March 25, 2014, before the market open. A conference call to discuss these results has been scheduled for Tuesday, March 25th at 10:00 AM (Eastern Daylight Time). A question and answer period will follow management's prepared remarks.
Flamel Technologies prices public offering at USD9.75 per ADS
M2 - Mon Mar 10, 4:12AM CDT
Drug delivery company Flamel Technologies (NASDAQ:FLML) said on Friday that it has priced its offering of American Depositary Shares (ADSs), representing 10,800,000 ordinary shares.
Flamel Technologies, S.A. Announces Pricing of Public Offering of American Depositary Shares
Marketwire - Fri Mar 07, 7:39AM CST
Flamel Technologies, S.A. (NASDAQ: FLML) today announced the pricing of an underwritten offering of American Depositary Shares (ADSs), representing 10,800,000 ordinary shares, at a price to the public of $9.75 per ADS. All of the ADSs in this offering are to be sold by Flamel. Flamel has granted the underwriters a 30-day option to purchase up to an additional 1,600,000 ADSs to cover over-allotments, if any, in connection with the offering. The offering is expected to close on March 12, 2014, subject to customary closing conditions.
Flamel Technologies plans to issue ADSs in public offering
M2 - Fri Mar 07, 6:02AM CST
Drug delivery company Flamel Technologies SA (NASDAQ:FLML) said on Thursday that it intends to sell American Depositary Shares (ADSs), representing its ordinary shares, in an underwritten public offering.